Physician profile
Mina Sinacori
NPI 1396718847
$17,655.19
in general payments reported to CMS, 2019-2025
45 companies · $742 in 2025
The $742 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,575 · 2020: $401 · 2021: $767 · 2022: $2,346 · 2023: $11K · 2024: $586 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,451 · Food and Beverage: $2,028 · Consulting Fee: $2,000 · Education: $88.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,450.65 |
| Food and Beverage | $2,027.58 |
| Consulting Fee | $2,000.00 |
| Education | $88.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $8,798.19 | 2021-2025 | Nexplanon |
| Exeltis, USA INC. | $2,944.77 | 2019-2025 | Slynd, Solosec |
| Scynexis, INC. | $1,159.78 | 2022 | |
| Abbvie INC. | $928.12 | 2019-2025 | Liletta, Lo Loestrin Fe, Orilissa |
| Mayne Pharma Commercial LLC | $579.23 | 2021-2024 | |
| Astellas Pharma US INC | $553.64 | 2022-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $401.91 | 2019-2025 | |
| Therapeuticsmd, INC. | $310.84 | 2019-2022 | |
| Novo Nordisk INC | $296.75 | 2020-2024 | Wegovy |
| Evofem Biosciences, INC. | $180.08 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $143.31 | 2020-2024 | Gardasil, Gardasil 9 |
| Hologic Sales and Service, LLC | $132.87 | 2019-2025 | Thinprep 2000 Processor, Myosure Tissue Removal Device, Novasure |
| Bayer Healthcare Pharmaceuticals INC. | $108.28 | 2019-2025 | |
| Allergan, INC. | $75.97 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $64.71 | 2023-2025 | Myfembree |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mina Sinacori listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.